600
Participants
Start Date
August 31, 2015
Primary Completion Date
May 23, 2022
Study Completion Date
May 23, 2022
MSB0011359C
Subjects would receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
National Taiwan University Hospital, Taipei
Mackay Memorial Hospital, Taipei
Taipei Medical University Hospital, Taipei
Institut Jules Bordet, Brussels
Cliniques Universitaires Saint-Luc, Brussels
Royal North Shore Hospital, St Leonards
Blacktown Hospital, Blacktown
Liverpool Hospital, Liverpool
St George Hospital, Kogarah
Calvary Mater Newcastle, Waratah
Port Macquarie Base Hospital, Port Macquarie
GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk
UZ Antwerpen, Edegem
Peter MacCallum Cancer Centre-East Melbourne, East Melbourne
Cabrini Hospital Malvern, Malvern
Border Medical Oncology Research Unit, Wodonga
C. H. U. Sart Tilman, Liège
Gallipoli Medical Research Foundation Ltd, Greenslopes
Tasman Oncology Research Ltd, Southport
The Queen Elizabeth Hospital, Woodville South
Grand Hôpital de Charleroi, Charleroi
Linear Clinical Research Limited, Nedlands
Fiona Stanley Hospital, Murdoch
Centre Hospitalier de l'Ardenne, Libramont
Universitair Ziekenhuis Gent, Ghent
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo
Charite Universitaetsmedizin Berlin - Campus Charite Mitte, Berlin
Hôpital de la Timone#, Marseille
Seoul National University Bundang Hospital, Seongnam-si
Penn State University Milton S. Hershey Medical Center, Hershey
Ospedale San Raffaele, Milan
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
IEO Istituto Europeo di Oncologia, Milan
National Cancer Institute, Bethesda
Centre Georges François Leclerc, Dijon
Virginia Cancer Specialists, PC, Fairfax
Virginia Oncology Associates - Hampton, Norfolk
Fondazione IRCCS Policlinico San Matteo, Pavia
University of North Carolina at Chapel Hill, Chapel Hill
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario Clinico San Carlos, Madrid
Hospital Universitario 12 de Octubre, Madrid
Centro Integral Oncologico Clara Campal, Madrid
Chungbuk National University Hospital, Cheongju-si
Medical University of South Carolina, Charleston
Greenville Hospital System University Medical Center (ITOR), Greenville
Southeastern Regional Medical Center, Newnan
University Cancer & Blood Center, LLC, Athens
Medizinische Hochschule Hannover, Hanover
Institut Claudius Regaud-Oncopole, Toulouse
CHU Bordeaux - Hôpital Saint André, Bordeaux
Sylvester Cancer Center, Miami
Institut Régional du Cancer de Montpellier, Montpellier
Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie
Tennessee Cancer Specialists, Knoxville
CHU de Grenoble - Hôpital Nord, Grenoble
Hospital Universitario Virgen Macarena, Seville
Hospital Universitario Virgen del Rocio, Seville
Case Comprehensive Cancer Center, Cleveland
ICO - Site René Gauducheau, Saint-Herblain
UC Health Clinical Trials Office, Cincinnati
Hospital Clinico Universitario de Valencia, Valencia
Hospital Universitari i Politecnic La Fe, Valencia
Henry Ford Health System, Detroit
Michigan State University, Lansing
Pusan National University Hospital, Busan
Cellex Koeln, Cologne
A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena
Azienda Ospedaliero Universitaria Pisana, Pisa
Centre Oscar Lambret, Lille
Washington University, St Louis
Centre Paul Strauss, Strasbourg
Centre Léon Bérard, Lyon
Centre Hospitalier de la Croix Rousse, Lyon
Metairie Oncologists, LLC, Metairie
Mary Crowley Cancer Research Centers, Dallas
Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris, Paris
Hôpital Saint-Louis, Paris
Groupe Hospitalier Pitie-Salpetriere, Paris
Texas Oncology, P.A. - Tyler, Tyler
Texas Oncology, P.A. - Fort Worth, Fort Worth
Oncology Consultants, P.A., Houston
University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics, Houston
South Texas Accelerated Research Therapeutics, LLC, San Antonio
Texas Oncology, P.A. - Austin, Austin
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli
Rocky Mountain Cancer Centers, LLP, Denver
Arizona Clinical Research Center, Tucson
Comprehensive Cancer Centers of Nevada, Las Vegas
Innovative Clinical Research Institute, Whittier
Pacific Oncology Associates, Escondido
Hôpital Henri Mondor, Créteil
California Pacific Medical Center, San Francisco
University of California Davis Health System, Sacramento
Compass Oncology, Vancouver
Eastern Connecticut Hematology/Oncology Assoc., Norwich
Dana Farber Cancer Institute, Boston
Rhode Island Hospital, Providence
Cross Cancer Institute, Edmonton
Centre Antoine Lacassagne, Nice
Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden
Policlinico Universitario Agostino Gemelli, Roma
National Cancer Center Hospital East, Kashiwa-shi
Kindai University Hospital, Osakasayama-shi
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Hospital Infanta Cristina, Badajoz
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Clinic i Provincial de Barcelona, Barcelona
Guy's Hospital, London
University College London Hospitals, London
The Christie, Manchester
Southampton General Hospital, Southampton
Beatson West of Scotland Cancer Centre, Glasgow
Northern Centre for Cancer Care, Newcastle upon Tyne
Queen Elizabeth Hospital, Birmingham
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY